CENTURY THERAPEUTICS INC. overview

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 Cash runway estimate extended into fourth quarter of 2026 PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ:...

- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - - Trial to evaluate and enhance clinical experience with CNTY-101 in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis - PHILADELPHIA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc. (NASDAQ: IPSC), an...

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024: Autoimmune Disease Cell Therapy Panel: 3:00 PM ET Presenter: Chad Cowan, Ph.D., Chief...

– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study – – CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the anticipated protective activity of Century’s proprietary...

– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to primary αβ CAR-T cells, allowing for control of tumors in vivo without the need for exogenous or engineered cytokines – – Posters include demonstration of advances in gene editing and transgene design that enable...

PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:30am...

- Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - - Chad Cowan, Ph.D., cell therapy pioneer, founder, and former CEO of Clade Therapeutics, appointed as Chief Scientific Officer - - Hy Levitsky, M.D., President of Research and Development, to transition to an advisor to Century - PHILADELPHIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc. (NASDAQ: IPSC), an innovative...

– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – – Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory – – Completed dose escalation for ELiPSE-1 and advancing into dose expansion in 2H 2024 – –...